Immunovaccine hires John Trizzino as ceo


Vaccine specialist brings 25 years of experience to the role

Immunovaccine, a Canadian developer of vaccines, has appointed John Trizzino as chief executive. He will also join the board of directors of the firm upon joining on 1 October.

Trizzino has focused his career on vaccine development, manufacturing and distribution in the US and worldwide.

He joins Immunovaccine from Novavax, a clinical-stage vaccine company in Rockville, Maryland, where he was senior vice president.

Prior to this, he held senior executive positions at MedImmune, acquired by AstraZeneca, and ID BioMedical, now part of GlaxoSmithKline.

He began his broad-based career in vaccines at Henry Schein.

‘As our development programme accelerates with a second cancer vaccine in the clinic, we are pleased to be joined by someone with John's experience in partnering, licensing and distribution,’ said Albert Scardino, chairman of Immunovaccine.

‘The next phase of our development includes expanding the commercial potential of our early stage research partnerships. That is John's specialism. He knows the public markets, private financing and government contracting, and with his broad experience in the biotechnology industry, we anticipate a high level of visibility for our pioneering delivery platform and our vaccines.’

Immunovaccine develops vaccines for treating cancer and for the prevention of infectious disease.

The firm's DepoVax platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses.